Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Fentanyl

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

32 API Suppliers, 11 USDMF, 10 CEP/COS, 3 JDMF, 1 EU WC, 4 KDMF, 13 NDC API, 10 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

89 Drugs in Development

89 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

545 FDF Dossiers, 71 FDA Orange Book, 367 Europe, 16 Canada, 45 Australia, 19 South Africa, 27 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

FILM, EXTENDED RELEASE;TRANSDERMAL - 100MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 12.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 25MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 37.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 50MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 75MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 4 DKSH, 2 Boai NKY Pharmaceuticals Ltd, 1 Nanjing Well Pharmaceutical, 1 Actylis, 1 Alcedo Pharmachem, 5 BASF, 1 Huzhou Sunflower Pharmaceutical, 1 Microlex e.U, 1 Novo Excipients

EXCIPIENTS BY APPLICATIONS

8 Topical, 6 Fillers, Diluents & Binders, 5 Direct Compression, 4 Thickeners and Stabilizers, 4 Rheology Modifiers, 3 Film Formers & Plasticizers, 2 Granulation, 2 Solubilizers, 1 Controlled & Modified Release, 1 Taste Masking, 1 Coating Systems & Additives

DIGITAL CONTENT

216 News #PharmaBuzz

216 News #PharmaBuzz

GLOBAL SALES INFORMATION

6 US Medicaid Prescriptions, 306 Regulatory FDF Prices, 14 Annual Reports

MARKET PLACE

5 APIs, 21 FDF Dossiers

PATENTS & EXCLUSIVITIES

68 US Patents, 6 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 11 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/11/2025	Aspen API	Netherlands	Fine Chemicals Corporation (Pty) Ltd. Cape Town ZA	R1-CEP 2005-233 - Rev 03	Fentanyl	2018-10-04	Valid	Chemical		1210
29/11/2025	Veranova	U.S.A	Johnson Matthey Pharmaceutical Materials West Deptford US	R1-CEP 2000-141 - Rev 03	Fentanyl	2013-03-04	Valid	Chemical		1210

Fentanyl

Fentanyl

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

32 API Suppliers

11 USDMF

10 CEP/COS

3 JDMF

1 EU WC

4 KDMF

13 NDC API

10 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

89 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

545 FDF Dossiers

71 FDA Orange Book

367 Europe

16 Canada

45 Australia

19 South Africa

27 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

FILM, EXTENDED RELEASE;TRANSDERMAL - 100MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 12.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 25MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 37.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 50MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 75MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma

4 DKSH

2 Boai NKY Pharmaceuticals Ltd

1 Nanjing Well Pharmaceutical

1 Actylis

1 Alcedo Pharmachem

5 BASF

1 Huzhou Sunflower Pharmaceutical

1 Microlex e.U

1 Novo Excipients

EXCIPIENTS BY APPLICATIONS

8 Topical

6 Fillers, Diluents & Binders

5 Direct Compression

4 Thickeners and Stabilizers

4 Rheology Modifiers

3 Film Formers & Plasticizers

2 Granulation

2 Solubilizers

1 Controlled & Modified Release

1 Taste Masking

1 Coating Systems & Additives

DIGITAL CONTENT

216 News #PharmaBuzz

GLOBAL SALES INFORMATION

6 US Medicaid Prescriptions

306 Regulatory FDF Prices

14 Annual Reports

MARKET PLACE

5 APIs

21 FDF Dossiers

PATENTS & EXCLUSIVITIES

68 US Patents

6 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM

11 Others

Filters

FILM, EXTENDED RELEASE;TRANSDERMAL - 100MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 12.5MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 25MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 37.5MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 50MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 75MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons